First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

被引：0
|
作者：
Zhang, Huilai
Cheng, Ying
Yang, Haiyan
Zhang, Liling
Zou, Liqun
Guo, Ye
Cao, Junning
Huang, Huiqiang
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Lyu, Jiaoyan
Fang, Yiqian
Cohen, Aileen
Zhou, Keshu
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[6] Shanghai East Hosp, Tongji Univ, Sch Med, Shanghai, Peoples R China
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[9] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[10] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[11] BeiGene Beijing Ltd, Beijing, Peoples R China
[12] BeiGene USA Inc, San Mateo, CA USA
[13] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7557
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [32] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
    de Vos, S
    Fernando, D
    Schenkein, DP
    Rosen, PJ
    BLOOD, 2005, 106 (11) : 267B - 267B
  • [33] Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Nowakowski, Grzegorz S.
    Yoon, Dok Hyun
    Joffe, Erel
    Zinzani, Pier Luigi
    Sabatelli, Lorenzo
    Waltl, Eva E.
    Alvero, Carmelita G.
    Hess, Georg
    Riedell, Peter A.
    Kim, Kibum
    Brixner, Diana
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
    Martin Garcia-Sancho, A.
    Baile, M.
    Rodriguez, G.
    Dlouhy, I.
    Sancho, J. M.
    Jarque, I.
    Gonzalez-Barca, E.
    Salar, A.
    Espeso, M.
    Grande, C.
    Bergua, J.
    Montes-Moreno, S.
    Redondo, A.
    Enjuanes, A.
    Campo, E.
    Lopez-Guillermo, A.
    Caballero, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
  • [35] Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients
    Veeraputhiran, Muthu
    Mehta, Amitkumar
    Alencar, Alvaro J.
    Modi, Dipenkumar
    Voorhees, Timothy J.
    Narkhede, Mayur
    BLOOD, 2022, 140 : 12089 - 12091
  • [36] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    BLOOD, 2022, 140 : 6635 - 6637
  • [38] An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Borchmann, P.
    Tam, C. S.
    Jaeger, U.
    McGuirk, J. P.
    Holte, H.
    Waller, E. K.
    Jaglowski, S. M.
    Bishop, M. R.
    Andreadis, C.
    Foley, S. R.
    Westin, J. R.
    Fleury, I.
    Ho, P. J.
    Mielke, S.
    Salles, G.
    Maziarz, R. T.
    Anak, Oe
    Pacaud, L. B.
    del Corral, C.
    Awasthi, R.
    Agoulnik, S.
    Tai, F.
    Schuster, S. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 37
  • [39] Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R)
    Hernandez-Ilizaliturri, F. J.
    Deeb, G.
    Zinzani, P. L.
    Pileri, S. A.
    Malik, F.
    Macon, W. R.
    Witzig, T. E.
    Goy, A.
    Czuczman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
12345